Julien [on for Liisa Bayko]'s questions to Editas Medicine (EDIT) leadership • Q3 2023
Question
Asked for the expected timing of a legal appeal decision, when to expect a substantial data update for TDT patients, and when the company will communicate the outcome of its regulatory path discussions with the FDA.
Answer
The company declined to comment on ongoing legal proceedings. They confirmed strong enrollment in the TDT trial but have not yet provided a timeline for a substantial data update. They will share the outcome of FDA discussions at an appropriate future time.